LONG PRODUCT DESCRIPTION

CJC-1295 MOD GRF 1-29 2mg is a research peptide product identified in its product name as the non-DAC form of CJC-1295, also known as Modified GRF (1-29). The stated quantity is 2mg. This distinction matters: the version without DAC should not be confused with CJC-1295 with DAC, which is a chemically different form. This page focuses on the product named, without attributing unverified performance, purity, testing or manufacturing claims to it.

Product overview

CJC-1295 MOD GRF 1-29 is associated with the growth hormone-releasing hormone (GHRH) research field. It is described in scientific and research references as a modified form of the 1-29 fragment of GHRH. The term without DAC indicates that the product is not the albumin-binding DAC form.

The product title specifies a quantity of 2mg. The brand, physical presentation, packaging type, excipients, salt form, purity, batch details and storage requirements have not been supplied for this listing. Customers should consult the product label and any accompanying manufacturer documentation for those details before making a purchasing decision.

For researchers comparing peptide references, distinguishing between the DAC and non-DAC forms is particularly important. They should not be treated as interchangeable names for an identical product. The scientific paper commonly cited in discussions of CJC-1295 describes an albumin-bioconjugated, long-acting analogue; it should not be used as proof of the properties of this 2mg non-DAC product. Read the PubMed paper on the DAC form.

Why choose CJC-1295 MOD GRF 1-29?

When evaluating a research peptide, the most useful starting point is an accurate product identity and transparent documentation. This listing identifies the compound as CJC-1295 MOD GRF 1-29, specifies that it is without DAC and states a quantity of 2mg.

These details help distinguish the listing from products described as CJC-1295 with DAC or from combination products containing additional compounds. The product name and stated quantity provide a starting point for comparing listings, but they do not independently establish purity, composition, suitability for a particular analytical method or batch consistency.

Before purchasing, researchers should review any available product label, certificate of analysis (if supplied), batch reference and manufacturer information. If these documents are not displayed, contact the supplier to ask whether they are available. Do not assume that a certificate, independent test or particular quality standard exists unless supporting documentation is provided.

Research information: Modified GRF (1-29)

Modified GRF (1-29) belongs to the research area concerned with growth hormone-releasing hormone and its analogues. GHRH is a peptide hormone involved in signalling pathways studied in relation to the pituitary gland. Modified peptide analogues are examined in scientific contexts to understand how changes to a peptide’s structure may affect its properties.

It is important to separate the research literature on different CJC-1295 forms. A frequently cited 2005 paper investigated albumin-bioconjugated GHRH analogues and identified the DAC-associated form as a long-lasting analogue in the experimental models described. That paper does not establish the pharmacokinetics, safety or effects of the non-DAC product listed here. View the 2005 study on PubMed.

A separate PubMed-indexed paper identified modified GRF (1-29) in an analytical investigation of seized powders. This is relevant as an example of analytical identification, not evidence of clinical effectiveness or suitability for human use. Read the analytical research paper.

Researchers reviewing this compound should therefore check the exact molecular identity and form described in the source material. Similar product names do not guarantee identical structures or experimental properties. Findings relating to CJC-1295 with DAC should not automatically be attributed to Modified GRF (1-29) without DAC.

Quality, documentation and supplier transparency

Reliable research purchasing begins with information that can be checked. For this product, the information currently supplied confirms the product name, its non-DAC designation and the stated 2mg quantity. It does not confirm independent laboratory testing, a purity percentage, GMP certification, pharmaceutical grade, sterility or a specific manufacturer.

Where available, buyers should review product-specific documentation and check that the product name, batch reference and stated quantity match the item being offered. If a Certificate of Analysis is provided, check that it identifies the relevant batch and explains the analytical method and results. A generic document that cannot be connected to the product batch is not the same as batch-specific evidence.

For UK regulatory context, the MHRA guidance on unlicensed medicinal products explains the framework for supplying unlicensed medicines for human use. The Human Medicines Regulations 2012 also set out UK requirements concerning medicinal products. A research-use label does not, by itself, determine a product’s legal status; classification depends on the product and its presentation and intended purpose.

Buying with confidence

Before ordering CJC-1295 MOD GRF 1-29, check the exact product name, DAC designation and stated quantity. Review the product information carefully and ask the supplier about any details that are important to your research, including physical format, packaging, batch identification and supporting documentation.

Customers should also review the website’s published checkout, contact and delivery information before placing an order. Where shipping terms or delivery timeframes are not displayed, contact the supplier for clarification rather than relying on assumptions.

For further background on peptide-related research and the distinction between compound identity and regulatory status, the US FDA’s information on CJC-1295-related substances provides a regulatory-science discussion. This is a US source and should not be interpreted as a statement of UK authorisation.

Important research-use notice

Where this product is supplied and marketed as a research-use material, it should be clearly labelled and handled only within the applicable research framework. It is not presented here as a medicine, treatment or product for human or veterinary administration. No dosing, reconstitution or administration instructions are provided. Buyers are responsible for checking applicable laws, institutional requirements and the supplier’s product documentation.